CRANBURY, N.J.--(BUSINESS WIRE)--July 20, 2006--Valera Pharmaceuticals, Inc. today announced a partnership with Spepharm Holding B.V. for the exclusive marketing and distribution rights to VANTAS® and SUPPRELIN®-LA in the European Union, Switzerland and Norway. Spepharm is a newly created entity backed by two leading life science investment firms TVM Capital and Sanders Morris Harris Inc.
